POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (10.21.2021, 6:07pm CEST, WHO):   U.S. 75,267    India 18,454    Brazil 12,969    United Kingdom 48,545    Russia 36,339    Turkey 29,760    France 5,922    Iran 11,770    Argentina 1,303    Spain 1,235    Italy 3,699    Germany 16,077    Mexico 4,220    Poland 5,592    Philippines 3,656    Ukraine 22,415    Malaysia 5,516    Netherlands 4,609    Iraq 1,388    Thailand 9,727    Czechia 3,276    Canada 2,275    Chile 1,228    Romania 16,110    Israel 1,021    Serbia 7,745    Kazakhstan 1,995    Cuba 1,550    Vietnam 3,646    Jordan 1,232    Hungary 2,361    Austria 3,865    Greece 3,252    Georgia 4,411    Belarus 2,076    Bulgaria 4,522    Azerbaijan 2,303    Slovakia 3,091    Croatia 3,053    Ireland 2,147    Venezuela 1,162    Lithuania 3,349    Denmark 1,127    South Korea 1,441    Moldova 2,068    Slovenia 2,145    Armenia 2,603    Latvia 2,935    Estonia 1,505    China 29    Singapore 3,862    New Zealand 104    Australia 2,150   

WHO validates Sinovac COVID-19 vaccine for emergency use

Christian Fernsby |
The World Health Organization (WHO) validated on Tuesday the CoronaVac COVID-19 vaccine developed by Chinese pharmaceutical company Sinovac for emergency use.

Article continues below




"I am happy to announce that the Sinovac coronavirus vaccine has been given WHO Emergency Use Listing (EUL) after being found to be safe, effective, and quality assured following two doses of the inactivated vaccine," WHO Director-General Tedros Adhanom Ghebreyesus said at a WHO press briefing on Tuesday.

"Furthermore, the easy storage requirements of CoronaVac make it very suitable for low resource settings," he added.

The CoronaVac vaccine, developed by Sinovac Life Sciences Co., Ltd. based in Beijing, is also an inactivated vaccine, like the other and the first COVID-19 vaccine from China - the Sinopharm vaccine, which was validated earlier last month for WHO emergency use.

Apart from the two Chinese vaccines, WHO has previously listed the COVID-19 vaccine developed by Pfizer/BioNTech, two versions of AstraZeneca/Oxford vaccine, the Janssen vaccine, and the Moderna vaccine for emergency use.

According to WHO's Strategic Advisory Group of Experts on Immunization (SAGE), the Sinovac vaccine is recommended for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks.

The vaccine efficacy results showed that the Sinovac vaccine prevented severe COVID-19 and hospitalization in 100 percent of the studied population.

However, as few people over 60 years old were enrolled in clinical trials, SAGE said the Sinovac vaccine's efficacy could not be estimated in this age group.

"There is no reason to believe that the vaccine has a different safety profile in older and younger populations," the WHO statement said, adding that SAGE is not recommending an upper age limit for the vaccine, because data collected in multiple countries and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons.

As in the cases of previously validated vaccines, WHO recommends that countries using the Sinovac vaccine in older age groups conduct safety and effectiveness monitoring to verify the expected impact and contribute to making the recommendation more robust for all countries.

Assessment by SAGE has shown that the Sinovac vaccine had been authorized by 32 countries or jurisdictions for use in adults 18 years or older, where 260 million doses have been distributed to the public in domestic and overseas markets.

No safety concerns have been identified from pre-clinical or repro/tox studies, while most adverse events were mild to moderate, such as pain at the injection site, headache, fatigue and myalgia.

As more than 80 percent of the COVID-19 vaccine doses globally have been administered in high-and upper-middle income countries and just 0.3 percent in low-income countries, according to WHO's statistics, the two Chinese vaccines, with WHO's validation for emergency use, are expected to accelerate vaccine roll-out in many low-and middle-income countries through purchase and delivery by the WHO-led COVAX international COVID-19 vaccine initiative.

China has already decided to provide 10 million COVID-19 vaccine doses to the COVAX initiative to meet the urgent needs of developing countries, a concrete step to deliver on the promise to make vaccines a global public good.


What to read next

Egypt receives raw materials to produce Sinovac COVID-19 vaccine
World-first COVID-19 alternating dose vaccine study launches in UK
Hong Kong approves China's Sinovac vaccine